

# ALIVER KICK-OFF MEETING

## WELCOME

---


23<sup>rd</sup> January 2017, London



# ALIVER Project overview


## Development of DIALIVE, a novel Liver Dialysis Device for the treatment of patients with Acute on Chronic Liver Failure (ACLF)





# The Problem

- Developing a Consortium
- Study in 29 Hospitals
- 1400 patients studied
- New Prognostic criteria defined



# The opportunity to alter the disease course

INITIAL GRADE	FINAL GRADE			
	No ACLF (n=165)	ACLF-1 (n=70)	ACLF-2 (n=59)	ACLF-3 (n=94)
<b>ACLF -1</b>				
Prevalence (n=202)	110 (54.5%)	49 (24.3%)	18 (8.9%)	25 (12.4%)
28-day tx-free mortality (n=190)	7/104 (6.7%)	10/47 (21.3%)	8/15 (53.3%)	21/24 (87.5%)
<b>ACLF -2</b>				
Prevalence (n=136)	47 (34.6%)	19 (14.0%)	35 (25.7%)	35 (25.7%)
28-day tx-free mortality (n=118)	1/42(2.4%)	2/17(11.8%)	8/27 (29.6%)	29/32 (90.63%)
<b>ACLF -3</b>				
Prevalence (n=50)	8 (16.0%)	2 (4.0%)	6 (12%)	34 (68%)
28-day tx-free mortality (n=45)	1/8 (12.5%)	0/2 (0.0%)	4/6 (66.7%)	28/29 (96.6%)